KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease.

Neitzel, Julia; Franzmeier, Nicolai; Rubinski, Anna; Dichgans, Martin; Brendel, Matthias; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Malik, Rainer; Ewers, Michael · Nat Commun · 2021

prospective_cohort · Level II

Where this comes from

Abstract

Klotho-VS heterozygosity (KL-VS<sup>het</sup>) is associated with reduced risk of Alzheimer's disease (AD). However, whether KL-VS<sup>het</sup> is associated with lower levels of pathologic tau, i.e., the key AD pathology driving neurodegeneration and cognitive decline, is unknown. Here, we assessed the interaction between KL-VS<sup>het</sup> and levels of beta-amyloid, a key driver of tau pathology, on the levels of PET-assessed neurofibrillary tau in 551 controls and patients across the AD continuum. KL-VS<sup>het</sup> showed lower cross-sectional and longitudinal increase in tau-PET per unit increase in amyloid-PET when compared to that of non-carriers. This association of KL-VS<sup>het</sup> on tau-PET was stronger in Klotho mRNA-expressing brain regions mapped onto a gene expression atlas. KL-VS<sup>het</sup> was related to better memory functions in amyloid-positive participants and this association was mediated by lower tau-PET. Amyloid-PET levels did not differ between KL-VS<sup>het</sup> carriers versus non-carriers. Together, our findings provide evidence to suggest a protective role of KL-VS<sup>het</sup> against amyloid-related tau pathology and tau-related memory impairments in elderly humans at risk of AD dementia.

Medical subject headings